Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remternetug Phase 1 in Alzheimer's Disease and Healthy Volunteers
NCT04451408Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2020
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of remternetug in Alzheimer's disease (AD) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) Considered Related to Study Drug. Started Jul 2020; status: completed.
02
Drugs
remternetug
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04451408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04451408.